Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bellus Health Inc (NQ: BLU )

8.250 -0.240 (-2.83%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 20, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 550,647
Open 8.530
Bid (Size) 8.250 (28)
Ask (Size) 8.270 (13)
Prev. Close 8.490
Today's Range 8.130 - 8.640
52wk Range 2.600 - 9.840
Shares Outstanding 55,378,660
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
BELLUS Health Reports First Quarter 2022 Financial Results and Business Highlights
From BELLUS Health Inc.
Via Business Wire

Performance

YTD
+3.25%
+3.25%
1 Month
+1.73%
+1.73%
3 Month
+29.31%
+29.31%
6 Month
+34.15%
+34.15%
1 Year
+112.63%
+112.63%

More News

Read More
BELLUS Health to Present Late-Breaking Clinical Data from the Phase 2b SOOTHE Trial of BLU-5937 at the ATS 2022 International Conference
From BELLUS Health Inc.
Via Business Wire
BELLUS Health to Participate in Multiple Upcoming Investor Conferences
From BELLUS Health Inc.
Via Business Wire
BELLUS Health Reports Year 2021 Financial Results and Business Highlights
From BELLUS Health Inc.
Via Business Wire
BELLUS Health Closes US$200 Million Public Offering of Common Shares in Canada and the United States
From BELLUS Health Inc.
Via Business Wire
BELLUS Health Announces Pricing of US$200 Million Public Offering in Canada and the United States
From BELLUS Health Inc.
Via Business Wire
The Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move Stocks
Via Benzinga
BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States
From BELLUS Health Inc.
Via Business Wire
58 Biggest Movers From Yesterday
Via Benzinga
Mid-Afternoon Market Update: Dow Tumbles Over 200 Points; BELLUS Health Shares Spike Higher
Via Benzinga
Mid-Day Market Update: Nasdaq Drops Over 100 Points; Foghorn Therapeutics Shares Surge
Via Benzinga
Topics Stocks
Exposures US Equities
40 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
ARNA Stock Alert: The Pfizer Deal That Has Arena Pharmaceuticals Rocketing Today
Via InvestorPlace
Here's Why Bellus Health Is Jumping Higher Today
Via The Motley Fool
NES, WTTR: The Deal That Has Penny Stock Nuverra Environmental Solutions Skyrocketing Today
Via InvestorPlace
BLU Stock Alert: The Study Data That Has BELLUS Health Blasting Higher Today
Via InvestorPlace
Mid-Morning Market Update: Markets Open Lower; Pfizer To Acquire Arena Pharmaceuticals
Via Benzinga
Topics Stocks
Exposures US Equities
BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
From BELLUS Health Inc.
Via Business Wire
The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setbacks For Merck's HIV Program, Decision Day For Daré
Via Benzinga
BELLUS Health Reports Third Quarter 2021 Financial Results and Business Highlights
From BELLUS Health Inc.
Via Business Wire
BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
From BELLUS Health Inc.
Via Business Wire
BELLUS Health Convenes Virtual Analyst Event to Discuss the Chronic Cough Landscape and its Selective P2X3 Antagonist BLU-5937
From BELLUS Health Inc.
Via Business Wire
BELLUS Health Announces Completion of Patient Enrollment in SOOTHE Phase 2b Trial for Refractory Chronic Cough and BLUEPRINT Phase 2a Trial for Chronic Pruritus Associated with Atopic Dermatitis
From BELLUS Health Inc.
Via Business Wire
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
Via Benzinga
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.